Dapagliflozin excels in chronic kidney disease, even in patients without diabetes
Adding dapagliflozin to standard of care (SOC) significantly reduces the risk of worsening kidney function, death due to kidney or cardiovascular (CV) disease, and all-cause mortality compared with SOC alone in patients with chronic kidney disease (CKD), regardless of whether they have type 2 diabetes (T2D), reveals the DAPA-CKD* trial — showing dapagliflozin charting new territories from diabetes to the renal realm.
How to control asthma well: Experts’ perspectives
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.

Hoạt chất mới

1 New

Công thức bào chế mới

1 New

Ký hiệu trên viên thuốc
Hình dạng
Dạng bào chế
Màu 1
Màu 2
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in